NeuroSense Therapeutics Ltd. (NRSN)
Develops drug treatments for brain diseases like ALS and Alzheimer's.
$0.58-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-46.5%
The outlook
NRSN trades near its 52-week lows, well below both its 50- and 200-day moving averages, though analyst consensus is strong buy with an average price target suggesting substantial upside from current levels. Coverage is light at three analysts, and the stock remains deeply depressed relative to its recent range.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 3 analysts
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +1025% vs current price
Analyst price target
~12-month · 3 analysts$6.50average target+1024.8% vs now
Now $0.58
Low $3.00High $9.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$20.9M
52-wk high
$2.09
52-wk low
$0.52
50-day avg
$0.75
200-day avg
$0.88
Trailing P/E
—